Serotonergic functioning as measured by the loudness dependence of auditory evoked potentials is related to a haplotype in the brain-derived neurotrophic factor (BDNF) gene

Journal of Psychiatric Research

Volumn 44, Issue 8, 2010, Pages 541-546

  Juckel, Georg ^a   Schumacher, Christiane ^a   Giegling, Ina ^b   Assion, Hans Jörg ^a   Mavrogiorgou, Paraskevi ^a   Pogarell, Oliver ^b   Mulert, Christoph ^b   Hegerl, Ulrich ^c   Norra, Christine ^a   Rujescu, Dan ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Brain derived neurotrophic factor (BDNF)

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BRAIN FUNCTION; CORRELATION ANALYSIS; ELECTROPHYSIOLOGY; EVOKED AUDITORY RESPONSE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROTRANSMISSION; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

ACOUSTIC STIMULATION; ADULT; AGED; AUDITORY CORTEX; BRAIN-DERIVED NEUROTROPHIC FACTOR; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; FUNCTIONAL LATERALITY; GENE FREQUENCY; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOACOUSTICS; SEROTONIN; YOUNG ADULT;

EID: 77952892043     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2009.11.006     Document Type: Article

References (53)

1. Altar C.A., Boylan C., Fritsche M., Jackson C., Hyman C., Lindsay R.M. The neurotrophins NT-4/5 and BDNF augment serotonin, dopamine, and GABAergic systems during behaviorally effective infusions to the substantia nigra. Experimental Neurology 1994, 130:31-40.
2. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
3. Beck K.D., Knüsel B., Hefti F. The nature of the trophic action of brain-derived neurotrophic factor, des(1-3)-insulin-like growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture. Neuroscience 1993, 52:855-866.
4. Beuten J., Ma J.Z., Payne T.J., Dupont R.T., Quezada P., Huang W., et al. Significant association of BDNF haplotypes in European-American male smokers but not in European-American female or African-American smokers. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2005, 139:73-80.
5. Choi M.J., Kang R.H., Lim S.W., Oh K.S., Lee M.S. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Research 2006, 1118:176-182.
6. Djalali S., Höltje M., Große G., Rothe T., Stroh T., Große J., et al. Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. Neurochemistry 2005, 92:616-627.
7. Eaton M.J., Staley J.K., Globus M.Y.T., Whittemore S.R. Developmental regulation of early serotonergic neuronal differentiation: the role of brain-derived neurotrophic factor and membrane depolarization. Developmental Biology 1995, 170:169-182.
8. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory ans hippocampal function. Cell 2003, 112:257-269.
9. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I and II disorders 1997, American Psychiatric Press, Washington.
10. Gallinat J., Bottlender R., Juckel G., Muncke-Puchner A., Stolz G., Kuss H.J., et al. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology 2000, 148:404-411.
11. Gonul A.S., Akdeniz F., Taneli F., Donat O., Eker C., Vahip S. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. European Archives of Psychiatry and Clinical Neuroscience 2005, 255:381-386.
12. Gratacòs M., González J.R., Mercader J.M., de Cid R., Urretavizcaya M., Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biological Psychiatry 2007, 61:911-922.
13. Hegerl U., Juckel G. Intensity dependence of auditory evoked potentials as indicator of central serotonergic neurotransmission - a new hypothesis. Biological Psychiatry 1993, 33:173-187.
14. Hegerl U., Gallinat J., Mrowinski D. Intensity dependence of auditory evoked dipole source activity. International Journal of Psychophysiology 1994, 17:1-13.
15. Hegerl U., Bottlender R., Gallinat J., Kuss H.J., Ackenheil M., Möller H.J. The serotonin syndrome scale: first results on validity. European Archives of Psychiatry and Clinical Neuroscience 1998, 248:96-103.
16. Huang T.L., Lee C.T., Liu Y.L. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. Journal of Psychiatric Research 2008, 42:521-525.
17. Hyman C., Juhasz M., Jackson C., Wright P., Ip N.Y., Lindsay R.M., et al. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. Journal of Neuroscience 1994, 14:335-347.
18. Juckel G., Molnár M., Hegerl U., Csépe V., Karmos G. Auditory evoked potentials as indicators of brain serotonergic activity - first evidence in cats. Biological Psychiatry 1997, 41:1181-1195.
19. Juckel G., Hegerl U., Molnár M., Csépe V., Karmos G. Auditory evoked potentials reflect serotonergic neuronal activity - a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology 1999, 21:710-716.
20. Juckel G., Mavrogiorgou P., Bredemeier S., Gallinat J., Frodl T., Schulz C., et al. Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders - a retrospective study. Pharmacopsychiatry 2004, 37:46-51.
21. Juckel G., Pogarell O., Augustin H., Mulert C., Müller-Siecheneder F., Frodl T., et al. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depression. Journal of Clinical Psychiatry 2007, 68:1206-1212.
22. Juckel G., Hegerl U., Giegling I., Mavrogiorgou P., Wutzler A., Schuhmacher C., et al. Association of 5-HT1B receptor polymorphisms with the loudness dependence of auditory evoked potentials in a community-based sample of healthy volunteers. American Journal of Medical Genetics Part B: Neuropsychiatric 2008, 147B:454-458.
23. Juckel G., Kawohl W., Giegling I., Mavrogiorgou P., Winter C., Pogarell O., et al. Association of catechol-O-methyltransferase variants with loudness dependence of auditory evoked potentials. Human Psychopharmacology 2008, 23:115-120.
24. Kanazawa T., Glatt S.J., Kia-Keating B., Yoneda H., Tsuang M.T. Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatric Genetics 2007, 17:165-170.
25. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Research 2002, 109:143-148.
26. Kawohl W., Giegling I., Mavrogiorgou P., Pogarell O., Mulert C., Möller H.J., et al. Association of functional polymorphisms in NOS1 and NOS3 with loudness dependence of auditory evoked potentials. International Journal of Neuropsychopharmacology 2008, 11:477-483.
27. Kenny P.J., File S.E., Rattray M. Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Brain Research. Molecular Brain Research 2000, 85:234-238.
28. Lang U.E., Hellweg R., Gallinat J. Association of BDNF serum concentrations with central serotonergic activity: evidence from auditory signal processing. Neuropsychopharmacology 2005, 30:1148-1153.
29. Le Foll B., Diaz J., Sokoloff P. A single cocaine exposure increases BDNF and D3 receptor expression: implications for drug-conditioning. Neuroreport 2005, 16:175-178.
30. Lee J., Fukumoto H., Orne J., Klucken J., Raju S., Vanderburg C.R., et al. Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Experimental Neurology 2005, 194:91-96.
31. Lindquist S., Schott B.H., Ban M., Compston D.A., Sawcer S., Sailer M. The BDNF-Val66Met polymorphism: implications for susceptibility to multiple sclerosis and severity of disease. Journal of Neuroimmunology 2005, 167:183-185.
32. Mamounas L.A., Blue M.E., Siuciak J.A., Altar C.A. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. Journal of Neuroscience 1995, 15:7929-7939.
33. Mamounas L.A., Altar C.A., Blue M.E., Kaplan D.R., Tessarollo L., Lyons W.E. BDNF promotes the regenerative sprouting, but not survival, of injured serotoninergic axons in the adult rat brain. Journal of Neuroscience 2000, 20:771-782.
34. Matrisciano F., Bonaccorso S., Ricciardi A., Scaccianoce S., Panaccione I., Wang L., et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. Journal of Psychiatric Research 2009, 43:247-254.
35. Monteleone P., Zanardini R., Tortorella A., Gennarelli M., Castaldo E., Canestrelli B., et al. The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder. Neuroscience Letters 2006, 406:133-137.
36. Mössner R., Daniel S., Albert D., Heils A., Okladnova O., Schmitt A., et al. Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochemistry International 2000, 36:197-202.
37. Müller D.J., de Luca V., Sicard T., King N., Strauss J., Kennedy J.L. Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. British Journal of Psychiatry 2006, 189:317-323.
38. Neves-Pereira M., Cheung J.K., Pasdar A., Zhang F., Breen G., Yates P., et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Molecular Psychiatry 2005, 10:208-212.
39. Okada T., Hashimoto R., Numakawa T., Iijima Y., Kosuga A., Tatsumi M., et al. A complex polymorphic region in the brain-derived neurotrophic factor (BDNF) gene confers susceptibility to bipolar disorder and affects transcriptional activity. Molecular Psychiatry 2006, 11:695-703.
40. Pogarell O., Tatsch K., Juckel G., Hamann C., Mulert C., Pöpperl G., et al. Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder. Neuropsychopharmacology 2004, 29:1910-1917.
41. Rice J.P., Reich T., Bucholz K.K., Neuman R.J., Fishman R., Rochberg N. Comparison of direct interview and family history diagnoses of alcohol dependence. Alcoholism, Clinical and Experimental Research 1995, 19:1018-1023.
42. Rumajogee P., Madeira A., Vergé D., Hamon M., Miquel M.C. Up-regulation of the neuronal serotoninergic phenotype in vitro: BDNF and cAMP share TrkB dependent mechanisms. Journal of Neurochemistry 2002, 83:1525-1528.
43. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., Poland G.A. Score tests for association of traits with haplotypes when linkage phase is ambiguous. American Journal of Human Genetics 2002, 70:425-434.
44. Scherg M., Picton T.W. Separation and identification of event-related potential components by brain electric source analysis. Electroencephalography and Clinical Neurophysiology Supplement 1991, 42:24-37.
45. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biological Psychiatry 2003, 54:70-75.
46. Siuciak J.A., Lewis D.R., Wiegand S.J., Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacology, Biochemistry, and Behaviour 1997, 56:131-137.
47. Siuciak J.A., Clark M.S., Rind H.B., Whettemore S.R., Russo A.F. BDNF induction of tryptophan hydroxylase mRNA levels in the rat brain. Journal of Neuroscience Research 1998, 52:149-158.
48. Spina M.B., Hyman C., Squinto S., Lindsay R.M. Brain-derived neurotrophic factor protects dopaminergic cells from 6-hydroxydopamine toxicity. Annals of the New York Academy of Sciences 1992, 648:348-350.
49. Strobel A., Debener S., Schmidt D., Hünnerkopf R., Lesch K.P., Brocke B. Allelic variation in serotonin transporter function associated with the intensity dependence of the auditory evoked potential. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2003, 118:41-47.
50. Surtees P.G., Wainwright N.W., Willis-Owen S.A., Sandhu M.S., Luben R., Day N.E., et al. No association between the BDNF Val66Met polymorphism and mood status in a non-clinical community sample of 7389 older adults. Journal of Psychiatric Research 2007, 41:404-409.
51. Tuchtenhagen F., Daumann J., Norra C., Gobbelé R., Becker S., Pelz S., et al. High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology 2000, 22:608-617.
52. Von Knorring L., Perris C. Biochemistry of the augmenting-reducing response in visual evoked potentials. Neuropsychobiology 1981, 7:1-8.
53. Wittchen H.U., Zaudig M., Fydrich T. Strukturiertes klinisches interview für DSM-IV, achse I und II 1997, Hogrefe, Goettingen.